Therapeutic effects of pazopanib treatment in patients with metastatic kidney cancer in real clinical practice
https://doi.org/10.17650/1726-9776-2018-14-4-37-47
Abstract
The current standard of treatment for patients with metastatic kidney cancer is targeted therapy, and the choice of a first-line drug is a difficult task for an oncologist in actual clinical practice. The article offers the data analysis, including information on 15 treated patients, and presents clinical efficacy of the targeted drug pazopanib as the first-line therapy in patients with metastatic kidney cancer with various sites of metastatic foci. The drug showed evidence of a convincing response to treatment, especially for metastatic foci in the lungs and adrenal glands.
About the Authors
P. G. Berezin
Tambov Regional Clinical Oncology Dispensary
Russian Federation
29V Moskovskaya St., Tambov 392000.
Competing Interests: The authors declare no conflict of interest.
Russian Federation
29V Moskovskaya St., Tambov 392000.
Competing Interests: The authors declare no conflict of interest.
V. V. Milovanov
Tambov Regional Clinical Oncology Dispensary
Russian Federation
29V Moskovskaya St., Tambov 392000.
Competing Interests: The authors declare no conflict of interest.
Russian Federation
29V Moskovskaya St., Tambov 392000.
Competing Interests: The authors declare no conflict of interest.
A. A. Ivannikov
Tambov Regional Clinical Oncology Dispensary
Russian Federation
29V Moskovskaya St., Tambov 392000.
Competing Interests: The authors declare no conflict of interest.
Russian Federation
29V Moskovskaya St., Tambov 392000.
Competing Interests: The authors declare no conflict of interest.
N. A. Ognerubov
Tambov Regional Clinical Oncology Dispensary; Derzhavin Tambov State University
Russian Federation
29V Moskovskaya St., Tambov 392000; 33 Internatsional’naya St., Tambov 392000.
Competing Interests: The authors declare no conflict of interest.
Russian Federation
29V Moskovskaya St., Tambov 392000; 33 Internatsional’naya St., Tambov 392000.
Competing Interests: The authors declare no conflict of interest.
References
1. International Agency for Research on Cancer. The GLOBOCAN project: cancer incidence and mortality worldwide in 2012. Available at: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx.
2. Malignant tumors in Russia in 2016 (morbidity and mortality). Eds.: A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena - filial FGBU “NMIRTS” Minzdrava Rossii, 2018. 250 p. (In Russ.).
3. Ljungberg B., Cowan A., Hanbury D.C. et al. Guidelines on Renal Cell Carcinoma. European Association of Urology 2012. Pp. 36-39.
4. Mikhaylenko D.S., Alekseev B.Ya., Efremov G.D., Kaprin A.D. Genetic characteristics of the non-clear cell renal cancer. Onkourologiya = Cancer Urology 2016;12(3):14—21. (In Russ.).
5. Ljungberg B., Handury D.C., Kuczyk M.A. et al. Guidelines on Renal Cell Cancer. European Association of Urology 2013.
6. Lonser R.R., Glenn C.M., Waltber M. et al. Von Hippel—Linday disease. Lanset 2003;361:2059-67.
7. Heng D. Y., Xie W., Regan M.M., et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascural endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27(34):5794-9. DOI: 10.1200/JCO.2008.21.4809. PMID: 19826129.
8. Motzer R.J., Bacik J., Schwartz L.H. et al. Prognostic factors for survival on previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004; 22(3): 454-63. DOI: 10.1200/JCO.2004.06.132. PMID: 25210086.
9. Escudier B., Porta C., Schiminger M. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;(Suppl 5):58—68. DOI: 10.1093/annonc/mdw328. PMID: 27664262.
10. Motzer R.J., Hutson T.E., Tomezak P. et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma.N Engl J Med 2007;356(2):115-24. DOI: 10.1056/NEJMoa 065044.PMID: 17215529.
11. Escudier B., Pluzanska A., Koralewski P. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trail. Lancet 2007;370(9605): 2103-11. DOI:10.1016/S0140-6736(07)61904-7. PMID:18156031.
12. Stemberg C.N., Davis I.D., Mardiak J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061-8. DOI: 10.1200/JCO.2009.23.9764. PMID: 20100962.
13. Motzer R.J., Hutson T.E., Tomezak P. et al. Overall survival and updated results for sunitinib compared with interferon-alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(22):3584-90. DOI: 10.1200/JCO.2008.20.1293. PMID: 19487381.
14. Escudier B., Bellmunt J., Negries S. et al. Phase III trail bevacizumab plus interferon alfa in patients with metastatic renal cell carcinoma (AVOREN): final results of overall survival. J Clin Oncol 2010;28(13):2144— 50. DOI: 10.1200/JOC.2009.26.7849. PIMD: 20368553.
15. Stemberg C.N., Hawkins R.E., Wagstaff J. et al. A randomized, double-blind, phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 2013;49(6):1287—96. DOI: 10.1016/j.ejca.2012.12.010. PMID: 23321547.
16. Motzer R.J., Hutson T.E., McCann L. et al. Overall survival in renal cell carcinoma with pazopanib versus sunitinib. N Engl J Med 2014;70(18):1769—70. DOI: 10.1056/NEJMc1400731. PMID: 24785224.
17. Escudier B.J., Porta C., Bono P. et al. Abstract and oral presentation at the American Society of Clinical Oncology Annual Congress 2012. J Clin Oncol 2012; 30(18 suppl):abstr. CRA4502.
18. Votrient. Summary of product characteris (In Russ.).
19. Hawkins R., Hodge R., Chen M. et al. Abstract and poster at Joint ECCO ESMO Congress, September 2009. Eur J Cancer Suppl 2009;7(3):abstr. 7119, poster 132.
20. Ljungberg B., Bensalah K., Bex A. et al. Volpe Guidelines on Renal Cell Carcinoma. European Association of Urology, 2018. Available at: http://www/uroweb.org/.
21. Volkova M.I., Klimov A.V., Chernyev V.A. Palliative nephrectomy: do all patiens require the surgery? Zlokachestvennye opukholi = Malignant Tumors 2016;(4, special issue 1):115—8. (In Russ).
Review
For citations:
Berezin P.G., Milovanov V.V., Ivannikov A.A., Ognerubov N.A. Therapeutic effects of pazopanib treatment in patients with metastatic kidney cancer in real clinical practice. Cancer Urology. 2018;14(4):37-47. (In Russ.) https://doi.org/10.17650/1726-9776-2018-14-4-37-47
Views:
2061
Email this article 